1 reports of this reaction
11.1% of all ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY reports
#4 most reported adverse reaction
APPLICATION SITE PRURITUS is the #4 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 1 FDA adverse event reports linking ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY to APPLICATION SITE PRURITUS. This represents approximately 11.1% of all 9 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY who experience application site pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE PRURITUS is a frequently reported adverse event for ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY, accounting for a significant proportion of all reports.
In addition to application site pruritus, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY:
The following drugs have also been linked to application site pruritus in FDA adverse event reports:
APPLICATION SITE PRURITUS has been reported as an adverse event in 1 FDA reports for ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE PRURITUS accounts for approximately 11.1% of all adverse event reports for ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY, making it a notable side effect.
If you experience application site pruritus while taking ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.